Core Viewpoint - The company, Anjisi Medical Technology Co., Ltd., has announced a differentiated cash dividend distribution plan, with a cash dividend of 1.3735 yuan per share, following the approval of its board and shareholders [1][2]. Dividend Distribution Plan - The company will distribute a cash dividend of 13.8 yuan for every 10 shares held, amounting to a total cash dividend distribution of approximately 111.2 million yuan (including tax) [2]. - The total share capital of the company is 80,978,794 shares, with 20,475 shares in the repurchase account, resulting in an actual participating share capital of 80,958,319 shares for the dividend distribution [2]. - The cash dividend distribution will not include capital reserve transfers or stock dividends [1][2]. Relevant Dates - The key dates for the dividend distribution are yet to be specified, including the record date, ex-dividend date, and cash dividend payment date [3]. Implementation of Distribution - The cash dividends will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered by the record date [4]. - Shareholders who have not completed designated transactions will have their dividends held by the China Securities Depository and Clearing Corporation until the transactions are completed [4]. Taxation Policies - For individual shareholders holding shares for over one year, the dividend income is exempt from personal income tax, resulting in a net cash dividend of 1.3735 yuan per share [5][6]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but the tax will be calculated based on the holding period when the shares are sold [5]. - The actual tax burden varies based on the holding period, with a 20% tax for shares held for one month or less, and a 10% tax for shares held between one month and one year [6]. Additional Information - The company will not withhold corporate income tax for institutional investors, who are responsible for determining their own tax obligations [8].

Key Points - Jiangnan Water received a stake increase from Lianan Life Insurance, reaching 5.03% of total shares [3] - Yingboer plans to transfer 100% equity of Zhuhai Dingyuan for 239 million yuan to optimize asset structure [4] - Chengbang Co. warns that its stock price fluctuations are not aligned with its fundamentals, as it has seen five consecutive trading days of price increases [6] - Weimais intends to invest 190 million yuan into its subsidiary for a new electric drive assembly project [7] - Fosun Pharma's subsidiary received EU GMP certification for its production facilities, indicating compliance with EU standards [8] - Jingwei Huikai plans to acquire an additional 12.44% stake in Nosi Micro, increasing its control in the semiconductor sector [9] - ST Tongmai will remove its delisting risk warning starting July 4, while continuing other risk warnings [10] - ST Modern seeks to apply for the removal of other risk warnings but will maintain delisting risk warnings [11] - Luxshare Precision is planning to issue H-shares for listing on the Hong Kong Stock Exchange [12] - Hainan Highway intends to purchase a 51% stake in Hainan Jiaokong Petrochemical, which will become a subsidiary [13] - Jucheng Co. plans to transfer 1.25% of its shares through a price inquiry [14] Performance Highlights - Foton Motor reported a 150.96% year-on-year increase in new energy vehicle sales for the first half of the year [15] - Jiangling Motors achieved a total vehicle sales of 172,700 units in the first half, up 8.15% year-on-year [16] - Changan Automobile's sales reached 1.3553 million units in the first half, with new energy vehicle sales growing by 49.05% [17] - Meinuohua expects a net profit increase of 142.84% to 174.52% for the first half of the year [18] - Jihong Co. anticipates a net profit increase of 55% to 65% for the first half of the year [19] - Nanjing Business Travel expects a net profit decrease of 67.4% to 78.27% for the first half of the year [20] - Madi Technology forecasts a net profit of 25 million to 27 million yuan, marking a turnaround from losses in the previous year [21] Major Contracts - Dash Intelligent signed a contract for an intelligent project worth 11.88 million yuan [22] - Jinyi Industrial won a bid for a 335 million yuan intercity railway materials procurement project [23] - Sichuan Road and Bridge signed a construction contract worth approximately 11.596 billion yuan [24] - Fulian Precision signed a cooperation framework agreement with Chuanfa Longmang for lithium battery material projects [26] Share Buybacks - Kweichow Moutai repurchased 72,000 shares in June, totaling 1.02 billion yuan [27] - Feiwo Technology plans to repurchase shares worth 25 million to 50 million yuan [28] - Nengte Technology intends to repurchase shares worth 300 million to 500 million yuan for capital reduction [29] - CATL has repurchased 6.641 million A-shares for a total of 1.551 billion yuan [30] Shareholding Changes - Renfu Pharmaceutical's shareholder plans to increase its stake by 1% to 2% [31] - Sanwei Xinan's shareholder intends to reduce its stake by up to 2% [33] - Data Port's shareholders plan to reduce their stakes by up to 2% [34] - Zhuzhou Design's controlling shareholders plan to reduce their stakes by up to 3% [35] - Tianji Co.'s controlling shareholders plan to reduce their stakes by up to 3% [36] - Anjisi's shareholders plan to reduce their stakes by up to 4% [37] Financing Activities - CITIC Securities received approval to issue up to 20 billion yuan in perpetual subordinated bonds [39]

证券代码：688581 证券简称：安杰思 公告编号：2025-045 杭州安杰思医学科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截止本公告披露日，公司股东苏州元生私募基金管理合伙企业（有限合伙） －苏州工业园区新建元二期创业投资企业（有限合伙）（以下简称"新建元"）持 有杭州安杰思医学科技股份有限公司（以下简称"安杰思医学"或"公司"）股份 3,233,835 股，占公司总股本的 3.9934%，其中持有的股份来源为公司首发前股份 数 2,309,882 股，通过公司 2023 年年度派送红股获得的股份数 923,953 股。股东 杭州天堂硅谷创业投资管理有限公司－宁波天堂硅谷正汇股权投资合伙企业（有 限合伙）（以下简称"天堂硅谷"）持有公司股份 1,622,700 股，占公司总股本的 2.0039%，其中持有的股份来源为公司首发前股份数 1,159,071 股，通过公司 2023 年年度派送红股获得的股份数 463,629 股。上 ...

2024 年 2 月 7 日，安杰思召开第二届董事会第十一次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意安杰思使用不低于人民 币 3,000 万元（含）不超过人民币 5,000 万元（含）的自有资金通过集中竞价的 交易方式回购安杰思已发行的部分人民币普通股（A 股）股票，回购股份将在未 来适宜时机全部用于员工持股计划或者股权激励，回购期限自第二届董事会第十 一次会议审议通过最终回购股份方案之日起不超过 12 个月。 中信证券股份有限公司 关于杭州安杰思医学科技股份有限公司 差异化权益分派的核查意见 中信证券股份有限公司（以下简称"保荐人"）作为杭州安杰思医学科技股 份有限公司（以下简称"安杰思"或"公司"）首次公开发行股票并在科创板上 市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等文件的要求，对安杰思差异化权益分派的事项进行了核查，具体情况如 下： 一、本次差异化权益分派的原因 2025 年 2 月 7 日，发行人披露《安杰思关于回购公司股份期限届满暨回购 实施结果的公告》 ...

证券代码：688581 证券简称：安杰思 公告编号：2025-044 杭州安杰思医学科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （1）差异化分红送转方案 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/8 | 2025/7/9 | 2025/7/9 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经杭州安杰思医学科技股份有限公司（以下简称"公司"） 2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 （公司回购专用证券账户除外）。 是否涉及差异化分红送转：是 每股分配比例 每股现金红利1.3735元 相关日期 根据《上海证券交易所上市公司自律监管指引第 7 号 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjiasi, a company in the medical device industry, which has a current PE ratio of 18.51, significantly lower than the industry average of 51.70 [1][2] - Anjiasi's total market capitalization is reported at 5.495 billion yuan, ranking 41st in the medical device sector based on PE ratio [1][2] - As of the first quarter of 2025, 11 institutions hold shares in Anjiasi, with a total of 17.7325 million shares valued at 1.26 billion yuan [1] Group 2 - Anjiasi specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, with key products including GI, EMR/ESD, and ERCP diagnostic series [1] - The company achieved significant government honors, including recognition as a "Zhejiang Provincial Enterprise Technology Center" and "Zhejiang Provincial High-Growth Biopharmaceutical Enterprise" [1] - In the latest financial report for the first quarter of 2025, Anjiasi reported revenue of 129 million yuan, a year-on-year increase of 15.27%, and a net profit of 56.2483 million yuan, reflecting a 6.57% increase [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjiasi Medical Technology Co., Ltd., which operates in the medical device industry, specifically focusing on minimally invasive endoscopic diagnostic and therapeutic instruments [1][2] - As of June 24, Anjiasi's closing price was 63.18 yuan, reflecting a 1.31% increase, with a rolling price-to-earnings (PE) ratio of 17.23 times and a total market capitalization of 5.116 billion yuan [1] - The average PE ratio for the medical device industry is 49.12 times, with a median of 36.07 times, positioning Anjiasi at the 41st rank within the industry [1][2] Group 2 - As of the first quarter of 2025, 11 institutions held shares in Anjiasi, including 6 funds and 5 other entities, with a total holding of 17.7325 million shares valued at 1.26 billion yuan [1] - Anjiasi's main products include GI series, EMR/ESD series, ERCP diagnostic series, and therapeutic instruments, contributing to its revenue growth [1] - The latest financial report for the first quarter of 2025 shows Anjiasi achieved an operating income of 129 million yuan, a year-on-year increase of 15.27%, and a net profit of 56.2483 million yuan, reflecting a year-on-year growth of 6.57%, with a gross profit margin of 70.68% [1]

得成为激励对象的下列情形： （1）最近12 个月内被证券交易所认定为不适当人选； （2）最近12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施； 杭州安杰思医学科技股份有限公司 监事会关于公司2025年限制性股票激励计划 授予激励对象名单的核查意见（截至授予日） 杭州安杰思医学科技股份有限公司（以下简称"公司"）监事会依据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简 称"《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称 "《上市规则》"）、《科创板上市公司自律监管指南第4 号——股权激励信 息披露》等法律、法规及规范性文件和《杭州安杰思医学科技股份有限公司章 程》（以下简称"《公司章程》"）的规定，对公司2025年限制性股票激励计 划（以下简称"本激励计划"）授予激励对象名单（截至授予日）进行审核， 发表核查意见如下： （5）法律法规规定不得参与上市公司股权激励的； （6）中国证监会认定的其他情形 ...

Meeting Overview - The third meeting of the Supervisory Board of Hangzhou Anjisi Medical Technology Co., Ltd. was held on June 17, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. Resolutions Passed - The Supervisory Board approved the proposal to grant restricted stock to three eligible incentive objects under the 2025 Restricted Stock Incentive Plan at a price of 46.16 yuan per share, totaling 16,089 shares [1][2]. - The Supervisory Board approved the proposal to postpone certain fundraising investment projects, stating that the decision was made based on the actual construction situation and did not harm shareholders' interests [2]. - The Supervisory Board approved the use of self-owned foreign exchange funds to pay for the required funds for fundraising projects, with a plan to replace the amount with raised funds, ensuring compliance with relevant regulations and improving fund utilization efficiency [3].

Core Viewpoint - The company has adjusted the cash dividend per share for the 2024 annual profit distribution from RMB 13.8000 to RMB 13.7350 due to changes in the number of shares eligible for distribution following a transfer of shares to an employee stock ownership plan [1][2][3] Summary by Sections Adjustment of Cash Dividend - The cash dividend per 10 shares has been adjusted from RMB 13.8000 (including tax) to RMB 13.7350 (including tax) [1] - The adjustment was necessary due to the transfer of 381,423 shares from the company's repurchase account to the employee stock ownership plan, affecting the number of shares eligible for the profit distribution [1][2] Previous Profit Distribution Plan - The original profit distribution plan approved on April 21, 2025, proposed a cash dividend of RMB 13.8000 per 10 shares, with a total cash dividend of RMB 111,196,116.48 (including tax) based on a total eligible share count of 80,576,896 shares [1][2] Revised Profit Distribution Plan - After the adjustment, the total number of shares eligible for profit distribution is now 80,958,319 shares, maintaining the total cash dividend amount at RMB 111,196,116.48 (including tax) [3] - The adjusted cash dividend per share is calculated as approximately RMB 1.3735 (including tax), leading to a total cash distribution of approximately RMB 111,196,251.15 (including tax) [3]